As a pioneer in brain health, Lundbeck understands that brain diseases cause havoc without bias. Millions of people across the globe, from all backgrounds and ethnicities, are impacted by psychiatric and neurological diseases. With 70+ years history in developing innovative treatments for brain diseases, we are keenly aware of the many obstacles that can prevent an individual from achieving brain health. Whether it be genetics, age, race, sex, ethnicity, socioeconomics or access to healthcare, understanding and fully evaluating the multitude of factors that influence a person’s health are key to both the development of good medicine and equitable advances in brain health.
At Lundbeck, we strive to improve the quality of life of all people living with brain diseases. We collaborate with the best minds in brain science to advance research and novel therapies. Co-operation across the health ecosystem ensures we incorporate a broad range of perspectives and approaches into our research programs. But we recognise that there is more we can—and must—do to ensure our work is equitable and our medicines are impactful for all people in need. Building an inclusive clinical trials infrastructure, one that reflects the full diversity of the intended treatment population, is an important step towards combatting health inequities and racial disparities in brain health.
Clinical trials for central nervous system disorders are high risk and fail at higher rates than other disease areas. Lundbeck has never shied away from this challenge, even redoubling our efforts as other companies have withdrawn from the space. We now bring the same level of commitment to improving diversity in our clinical trials because it is true to our purpose of restoring brain health, so every person can be their best.
Lundbeck is committed to implementing the following strategies and has invested in systems to monitor, track, and implement. To guide our efforts, the Lundbeck Diversity Steering Team will assess and drive efforts in this area and monitor our progress against the Lundbeck Clinical Trial Diversity Principles:
We are signees to the PhRMA Principles on Conduct of Clinical Trials & Communication of Clinical Trial Results, the first-ever industry wide principles on clinical trial diversity.
We pursue our business purpose guided by several pillars and our Code of Conduct.
Our policy for scientific publications and responsible clinical data sharing.
A specialist pharmaceutical company focused exclusively on brain diseases.
UK-NOTPR-0547 | April 2022